NasdaqGM:KYMRBiotechs
New Clinical Results and Big-Pharma Partnerships Might Change The Case For Investing In Kymera Therapeutics (KYMR)
Earlier this past week, Kymera Therapeutics announced positive results from its first KT-621 clinical trial, which delivered strong efficacy and a placebo-like safety profile, alongside new collaborations with Gilead and Sanofi and disclosure of a cash reserve near US$1 billion by July's end.
An important takeaway is that Kymera's strengthened pipeline through high-profile partnerships and a substantial cash runway may provide meaningful support for future research and development...